{"prompt": "['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '(manual or automated) area in accordance with the labeled storage conditions', 'with access limited to the investigator and authorized site staff.', 'The investigator, institution, or the head of the medical institution (where', 'applicable) is responsible for study treatment accountability, reconciliation, and', 'record maintenance (ie, receipt, reconciliation, and final disposition of records).', 'Further guidance and information for the final disposition of unused study', 'treatment are provided in the SRM.', 'Precaution will be taken to avoid direct contact with the study treatment. Under', 'normal conditions of handling and administration, study treatment is not expected', 'to pose significant safety risks to site staff. In the case of unintentional', 'occupational exposure notify the monitor, Medical Monitor and/or GSK study', 'contact.', 'A Material Safety Data Sheet MSDS)/equivalent document describing', 'occupational hazards and recommended handling precautions either will be', 'provided to the investigator, where this is required by local laws, or is available', 'upon request from GSK.', '7.6.', 'Treatment Compliance', 'When participants are dosed at the site, they will receive study treatment directly', 'from the investigator or designee, under medical supervision. The date and time of', 'each dose administered in the clinic will be recorded in the source documents. The', 'dose of study treatment and study participant identification will be confirmed at the', 'time of dosing by a member of the study site staff other than the person', 'administering the study treatment.', 'When participants self-administer study treatment(s) at home, compliance with study', 'treatment administration will be assessed through querying the participant during the', 'site visits and documented in the source documents and CRF. In addition,', 'participants will be asked to confirm study administration each day in the daily', 'ediary.', 'Study participants who are not compliant with study treatment administration', 'requirements should be re-educated on the importance of treatment compliance.', 'Every effort should be made to keep participants in the study. Participants who', 'continue to be non-compliant after several attempts to re-educate may be', 'discontinued after consultation with the GSK study team.', '7.7.', 'Concomitant Therapy', 'Any medication or vaccine (including over-the-counter or prescription medicines,', 'vitamins, and/or herbal supplements) that the participant is receiving at the time of', 'enrolment or receives during the study must be recorded along with:', 'reason for use', 'dates of administration including start and end dates', '31']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'dosage information including dose and frequency', 'The Medical Monitor should be contacted if there are any questions regarding', 'concomitant or prior therapy.', 'The following COPD medications are permitted during the study, at the discretion of the', 'GSK Medical Monitor and/or Investigator:', 'Inhaled COPD maintenance medications (e.g. long acting bronchodilator', 'medications (i.e. LAMA, LABA) and long-acting bronchodilator combination', 'therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled steroid', 'combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)', 'Short courses of oral corticosteroids and/or antibiotics (including macrolides)', 'are permitted for the acute treatment of exacerbations of COPD and should not', 'exceed 21 days. This use must be recorded as an HCRU exacerbation event.', 'The following medications are prohibited from the screening visit until after completion', 'of the follow up visit:', 'Chronic use of macrolide antibiotics for the prevention of COPD exacerbations.', 'Examples of chronic use include daily or two-three times per week for at least', '3', 'months.', 'Oral or injectable CYP3A4 or BCRP substrates with narrow therapeutic index', '(CYP3A4 substrates include, but are not limited to, alfentanil, cyclosporine,', 'dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus,', 'tacrolimus, and theophylline; BCRP substrates include, but are not limited to,', 'topotecan.', 'Phosphodiesterase-4 inhibitors (e.g. roflumilast)', 'Broad spectrum phosphodiesterase inhibitors (e.g. theophylline)', 'GSK will not supply rescue medication. Participants may continue to use and should', 'obtain rescue medication(s) through via their usual route. The following rescue', 'medications may be used:', 'Short acting beta agonists (SABA)(e.g., albuterol/salbutamol)', 'Short acting muscarinic antagonists (SAMA)(e.g., ipratropium)', 'Short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb,', 'Combivent)', 'The use of rescue medications is allowable at any time during the study. Participants', 'should record in the daily e-diary the number of puffs of rescue medication(s) over each', '24 hour period. Data from the MDI sensor device will be electronically captured and', 'transmitted to GSK.', 'Annual influenza vaccine is recommended for patients with COPD but is not required for', 'participation in this study. Influenza vaccination is permitted during the study and should', '32']\n\n###\n\n", "completion": "END"}